David Cheng
Hematology & Oncology · Fremont, CANPI 1104892652
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 529 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 17.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $4,460 and has fallen 99.3% since, to $31 in 2024.
Across 529 payments — averaging $17.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$2K
- Novo Nordisk$1K
- AstraZeneca$803
- Amgen$669
- Gilead$583
- Johnson & Johnson$576
- plus $4K from 33 others
What the payments were for
- Food & beverage$9,383100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 108 | $1,625 |
| Novo Nordisk | 77 | $1,066 |
| AstraZeneca(2 entities) | 42 | $803 |
| Amgen | 28 | $669 |
| Gilead | 39 | $583 |
| Johnson & Johnson(2 entities) | 28 | $576 |
| Lilly USA, LLC | 28 | $544 |
| Boehringer Ingelheim | 27 | $526 |
| GSK | 23 | $436 |
| Seagen Inc. | 15 | $388 |
| Pfizer | 14 | $355 |
| Bayer | 27 | $320 |
| Merck | 8 | $176 |
| Esperion Therapeutics, Inc. | 7 | $154 |
| Pharmacyclics LLC, An Abbvie Company | 5 | $129 |
| Novartis | 6 | $117 |
| Ironwood Pharmaceuticals, Inc | 5 | $112 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $104 |
| Epizyme, Inc. | 6 | $94 |
| Sanofi | 4 | $91 |
| EMD Serono, Inc. | 3 | $60 |
| Genentech USA, Inc. | 3 | $56 |
| Daiichi Sankyo Inc. | 2 | $47 |
| IBSA Pharma Inc. | 2 | $43 |
| Eisai Inc. | 2 | $31 |
| Radius Health, Inc. | 1 | $27 |
| AbbVie | 1 | $26 |
| Rigel Pharmaceuticals, Inc. | 1 | $24 |
| Abbott | 1 | $23 |
| Incyte Corporation | 1 | $22 |
| Dova Pharmaceuticals | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Astellas Pharma US Inc | 1 | $21 |
| Arbor Pharmaceuticals, Inc. | 1 | $20 |
| Mylan Institutional Inc. | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
How this compares
$9,392 in reported general payments places this provider in the 65th percentile of 1,363 hematology & oncology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Azithromycin | 18 | $54 |
| Famotidine | 11 | $53 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Fremont
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
- Robert VescioWest Hollywood$1.1M
- Kevin KellyLos Angeles$894K
- Johnny ChangEncino$884K
- Nitin RohatgiSacramento$814K
- Omid HamidSanta Monica$809K
- Catherine CoombsOrange$786K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.